

CURRICULUM VITAE

Name	DIERICKX O. Lawrence	
Birth Date / Citizen	01/09/1967/ Belgium	
Academic Title	M.D., PhD	
Institution	Institut Claudius Regaud Cancer Comprehensive Center IUCT-O, Nuclear Medicine 1 avenue Irène Joliot Curie 31059 TOULOUSE Cedex 9	Phone : (+33) 5 31 15 56 29 e-mail : dierickx.lawrence@iuct-oncopole.fr Mobile : 00 33 6 81 76 19 89
Present Professional status	Full time MD nuclear medicine specialist Center coordinator of the university center of excellence for neuroendocrine tumors Toulouse since 2019	
Professional Education	Medicine: state university Gent, Belgium: 1993; nuclear medicine: Free university Brussels: 1999; master research 2009 and PhD: Université P Sabatiers Toulouse 2016. Work as nuclear medicine physician in Belgium; Boston, USA; Riyadh SA; France I understand, speak and write Dutch, French and English	
Academic activity	Several formations within frame of university, inter university and on invitation	
Experience in clinical trials	Phase I: yes; phase II: yes; phase III: yes	
Research	UMR 1037 team 14 'individualisation of oncological treatment' CRCT Toulouse Invited speaker for AAA and IPSEN	
Publications:	<p>Place de la radiothérapie interne vectorisée dans le traitement des tumeurs neuroendocrines Frédéric Courbon, Lawrence Dierickx, Rosine Guimbaud Hépatogastro-Oncologie digestive 2016, 23 (supplément2), 39-50</p> <p>Evaluation of 2 diuretic 18Fluorine-Fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intra-pelvic cancer. Dierickx LO, Derclé L, Chaltiel L, Caselles O, Brillouet S, Zerdoud S, Courbon F. Q J Nucl Med Mol Imaging. 2017 Mar 29. doi: 10.23736/S1824-4785.17.02912-0. [Epub ahead of print] PMID: 28358186</p> <p>Evaluation of the interaction of amino acid infusion on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors Puzkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E Clin Pharmacokinet. 2019 Feb 58(2):213-222</p> <p>Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy Vija L, Dierickx L, Courbon F Ann Endocrinol (Paris). 2019 Jun;80(3):166-171. doi: 10.1016/j.ando.2019.04.005. Epub 2019 Apr 11. PMID: 31053248</p> <p>Successful and Safe Treatment With 177Lu-DOTATATE (Lutathera) of Progressive Metastatic Pancreatic Neuroendocrine Tumor Under Hemodialysis. Dierickx LO, Brillouet S, Mokrane F, Bensafi A, Guimbaud R. Clin Nucl Med. 2020 Sep;45(9):e400-e402. Clin Nucl Med. 2020. PMID: 32701804</p> <p>Imaging-guided precision medicine in non-resectable gastro-entéro-pancreatic neuroendocrine tumors: A step-by-step approach. Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson FL, Seban RD, Zadro C, Dierickx L, Chougnet CN, Partouche E, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Derclé L. Eur J Radiol. 2020 Jan;122:108743. doi: 10.1016/j.ejrad.2019.108743. Epub 2019 Nov 12. PMID: 31783345</p> <p>Poster ASCO 2021 : Efficacy and safety of 177Lu-DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective registry Dominique Clement, Shaunak Navalkissoor, Rajaventhana Srirajaskanthan, Frédéric Courbon, Lawrence Dierickx, Amy Eccles, Valerie Lewington, Mercedes Mitjavila, Juan Carlos Percovich, Benoît Lequoy, Beilei He, Ilya Folitar, John Ramage</p>	



**INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE**
Oncopole

Date: 10/05/2021